-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Barinthus Biotherapeutics, Lowers Price Target to $3

Benzinga·01/13/2025 12:11:11
Listen to the news
HC Wainwright & Co. analyst Yi Chen maintains Barinthus Biotherapeutics (NASDAQ:BRNS) with a Buy and lowers the price target from $5 to $3.